

**Biocon Biologics Belgium****BALANCE SHEET AS AT March 31, 2024**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>March 31, 2024</u>
<b>ASSETS</b>		
<b>Non-current assets</b>		
Deferred tax asset (net)		28
<b>Total non-current assets</b>		<b>28</b>
<b>Current assets</b>		
(i) Trade receivables	1	329
(ii) Cash and cash equivalents	2	146
<b>Total current assets</b>		<b>475</b>
<b>TOTAL</b>		<b>503</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	3	17
Other equity	4	29
<b>Total equity</b>		<b>45</b>
<b>Current liabilities</b>		
Financial liabilities		
(i) Trade payables	5	337
Income-tax liability (net)		38
Provisions	6	42
Other current liabilities	7	41
<b>Total current liabilities</b>		<b>458</b>
<b>TOTAL</b>		<b>503</b>

**Biocon Biologics Belgium****STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED MARCH 31, 2024**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>Period ended</u> <u>March 31, 2024</u>
<b>Income</b>		
Other operating income	8	843
<b>Total revenue (I)</b>		<b>843</b>
<b>Expenses</b>		
Purchases of traded goods	9	2
Employee benefits expense	10	633
Other expenses	11	170
<b>Total expenses (II)</b>		<b>805</b>
<b>Profit before tax</b>		<b>38</b>
Tax expense		
Current tax		38
Deferred Tax		(28)
<b>Total tax expense</b>		<b>10</b>
<b>Profit for the period</b>		<b>29</b>

**Biocon Biologics Belgium****STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED MARCH 31, 2024**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<b>Period ended March 31, 2024</b>
<b>I Cash flows from operating activities</b>	
Profit after tax	29
<u>Adjustments to reconcile profit before tax to net cash flows:</u>	
Tax expense	10
Operating profit before working capital changes	<u>38</u>
<b>Movements in working capital</b>	
Decrease/(Increase) in trade receivables	(329)
Increase in trade inventories	-
Increase in trade payable, other liabilities and provisions	420
<b>Cash generated from operations</b>	<u>130</u>
Direct taxes paid	-
<b>Net cash flow generated from operating activities</b>	<u><u>130</u></u>
<b>IV Net increase/(decrease) in cash and cash equivalents (I + II + III)</b>	<b>146</b>
V Effect of exchange differences on cash and cash equivalents held in foreign currency	-
VI Cash and cash equivalents at the beginning of the year	-
<b>VIII Cash and cash equivalents at the end of the year (IV + V + VI)</b>	<u><u>146</u></u>
<b>Reconciliation of cash and cash equivalents as per statement of cash flow</b>	
<b>Cash and cash equivalents</b>	
Balances with banks - on current accounts	146
Cash on hand	-
	<u>146</u>
<b>Total cash and cash equivalents [Refer note 2]</b>	<u><u>146</u></u>

**Biocon Biologics Belgium****Notes to financial statements for the period ended March 31, 2024**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

**March 31, 2024****1. Trade receivables****Other Receivables**

Outstanding for a period less than six months from the date they are due for payment

Unsecured, considered good

329

**329****2. Cash and cash equivalents**

Balances with banks:

On current accounts

146

**146****3. Share capital**

16,500 Equity share of EUR 1 each

17

**17****4. Other equity****Surplus/(deficit) in the statement of profit and loss**

Balance as per the last financial statements

-

Profit / (Loss) for the period

29

**Net surplus/(deficit) in the statement of profit and loss****29****Total other equity****29****5. Trade payables****338****6. Provisions****Current**

Compensated absences

42

**42****7. Other liabilities****(a) Current liabilities**

Statutory liabilities

41

**41**

**Biocon Biologics Belgium****Notes to financial statements for the period ended March 31, 2024**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<b>Period ended March 31, 2024</b>
<b>8. Other operating income</b>	
Support service cross charge to Group Companies	843
	<u>843</u>
<b>9. Purchase of traded goods</b>	2
	<u>2</u>
<b>10. Employee benefits expense</b>	
Salaries, wages and bonus	633
	<u>633</u>
<b>11. Other expenses</b>	
Rent	40
Legal and professional fees	52
Travelling and conveyance	21
Sales promotion expenses	47
Communication expenses	2
Miscellaneous expenses	4
Insurance Charges	4
	<u>170</u>